• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

作者信息

Sniderman A D, Bergeron J, Frohlich J

机构信息

Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Ave. W, Montreal QC H3A 1A1.

出版信息

CMAJ. 2001 Jan 9;164(1):44-7.

PMID:11209748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC80634/
Abstract
摘要

相似文献

1
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.载脂蛋白B与脂蛋白脂质：来自AFCAPS/TexCAPS试验的重要经验教训。
CMAJ. 2001 Jan 9;164(1):44-7.
2
Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).确立他汀类药物在低至中度风险一级预防中的益处：空军/德克萨斯冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）。
Atheroscler Suppl. 2007 Aug;8(2):3-8. doi: 10.1016/j.atherosclerosissup.2007.02.002. Epub 2007 Jun 27.
3
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.洛伐他汀对胆固醇水平正常的男性和女性急性冠脉事件的一级预防：空军/德州冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）的结果
JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615.
4
To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?选非高密度脂蛋白胆固醇还是载脂蛋白B：非高密度脂蛋白胆固醇能否充分替代载脂蛋白B？
Mayo Clin Proc. 2010 May;85(5):446-50. doi: 10.4065/mcp.2010.0058.
5
Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.肝素诱导的体外低密度脂蛋白沉淀（HELP）治疗期间血浆脂质和载脂蛋白水平的变化。
Am J Cardiol. 1995 Jun 1;75(16):1124-9. doi: 10.1016/s0002-9149(99)80743-7.
6
Primary prevention of coronary heart disease: implications of the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS).
Curr Cardiol Rep. 2000 Sep;2(5):439-44. doi: 10.1007/s11886-000-0058-6.
7
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.空军/德克萨斯冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）：洛伐他汀长期治疗女性的疗效和耐受性
J Womens Health Gend Based Med. 2001 Dec;10(10):971-81. doi: 10.1089/152460901317193549.
8
Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.低密度脂蛋白胆固醇、载脂蛋白 B 与冠心病风险：从家族性高脂血症到基因组学。
Biol Res Nurs. 2013 Jul;15(3):292-308. doi: 10.1177/1099800412436967. Epub 2012 Apr 23.
9
[How to manage lipid profiles and their interpretation in patients with coronary heart disease?].[如何管理冠心病患者的血脂谱及其解读？]
Presse Med. 2009 Jun;38(6):958-63. doi: 10.1016/j.lpm.2009.03.004. Epub 2009 Apr 18.
10
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.洛伐他汀在肾病综合征中的生理作用机制。
J Lipid Res. 1995 Jan;36(1):188-99.

引用本文的文献

1
Cholesterols, Apolipoproteins, and Their Associations with the Presence and Severity of Diabetic Retinopathy: A Systematic Review.胆固醇、载脂蛋白及其与糖尿病视网膜病变的存在和严重程度的关联：一项系统评价
Vision (Basel). 2022 Dec 16;6(4):77. doi: 10.3390/vision6040077.
2
[Not Available].[无可用内容]。
Can Fam Physician. 2019 Jun;65(6):e251-e260.
3
Normal-weight central obesity: Unique hazard of the toxic waist.正常体重中心型肥胖：有毒腰围的独特危害。
Can Fam Physician. 2019 Jun;65(6):399-408.
4
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.识别和管理动脉粥样硬化性血脂异常的方法：肥胖和糖尿病的代谢后果。
Can Fam Physician. 2013 Nov;59(11):1169-80.
5
Comparative account of serum lipids, lipoproteins and apolipoprotein-B in patients of coronary artery disease.冠状动脉疾病患者血清脂质、脂蛋白及载脂蛋白B的比较研究
Indian J Clin Biochem. 2004 Jan;19(1):10-3. doi: 10.1007/BF02872381.
6
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.与阿托伐他汀单药治疗相比，缓释烟酸与辛伐他汀联合使用可产生更低的致动脉粥样硬化血脂谱。
Vasc Health Risk Manag. 2010 Nov 24;6:1065-75. doi: 10.2147/VHRM.S14053.
7
Dysfunctional high-density lipoprotein.功能失调的高密度脂蛋白
Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):156-62. doi: 10.1097/med.0b013e32832922fc.
8
Is it LDL particle size or number that correlates with risk for cardiovascular disease?与心血管疾病风险相关的是低密度脂蛋白（LDL）颗粒大小还是数量？
Curr Atheroscler Rep. 2008 Oct;10(5):377-85. doi: 10.1007/s11883-008-0059-2.
9
Common problems in the management of hypertriglyceridemia.高甘油三酯血症管理中的常见问题。
CMAJ. 2002 Nov 26;167(11):1261-6.

本文引用的文献

1
The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary.心血管专科医生在心血管疾病预防中的作用——执行摘要。
Can J Cardiol. 1999 Dec;15 Suppl G:7G-16G.
2
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).空军/德克萨斯冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）中基线和治疗期间血脂参数与首次急性主要冠状动脉事件的关系。
Circulation. 2000 Feb 8;101(5):477-84. doi: 10.1161/01.cir.101.5.477.
3
LDL size and risk of coronary heart disease in elderly men and women.
Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2742-8. doi: 10.1161/01.atv.19.11.2742.
4
The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.冠状动脉搭桥术后积极与适度降低低密度脂蛋白胆固醇及低剂量抗凝对血脂、载脂蛋白和脂蛋白家族的影响试验
Atherosclerosis. 1999 Oct;146(2):369-79. doi: 10.1016/s0021-9150(99)00151-3.
5
Thrombogenic factors and recurrent coronary events.
Circulation. 1999 May 18;99(19):2517-22. doi: 10.1161/01.cir.99.19.2517.
6
Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group.加拿大成年人的血浆脂质和脂蛋白参考值以及血脂蛋白异常血症的患病率。加拿大心脏健康调查研究组。
Can J Cardiol. 1999 Apr;15(4):434-44.
7
Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.加拿大两个省份（魁北克省和萨斯喀彻温省）人群血浆载脂蛋白A-I和B的参考值及其与非脂质风险因素的关联。加拿大心脏健康调查研究小组。
Can J Cardiol. 1999 Apr;15(4):409-18.
8
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.冠状动脉疾病消退的一种新病理生理机制的证据：肝脂肪酶介导的低密度脂蛋白密度变化。
Circulation. 1999 Apr 20;99(15):1959-64. doi: 10.1161/01.cir.99.15.1959.
9
Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):605-10. doi: 10.1161/01.atv.19.3.605.
10
The atherogenic lipoprotein phenotype and vascular endothelial dysfunction.动脉粥样硬化性脂蛋白表型与血管内皮功能障碍。
Atherosclerosis. 1998 Jun;138(2):229-35. doi: 10.1016/s0021-9150(98)00037-9.